TY - JOUR
T1 - Diagnostic evaluation of the amastin protein from Leishmania infantum in canine and human visceral leishmaniasis and immunogenicity in human cells derived from patients and healthy controls
AU - Vale, Danniele L.
AU - Dias, Daniel S.
AU - Machado, Amanda S.
AU - Ribeiro, Patrícia A.F.
AU - Lage, Daniela P.
AU - Costa, Lourena E.
AU - Steiner, Bethina T.
AU - Tavares, Grasiele S.V.
AU - Ramos, Fernanda F.
AU - Martínez-Rodrigo, Abel
AU - Chávez-Fumagalli, Miguel A.
AU - Caligiorne, Rachel B.
AU - de Magalhães-Soares, Danielle F.
AU - Silveira, Julia A.G.
AU - Machado-de-Ávila, Ricardo A.
AU - Teixeira, Antônio L.
AU - Coelho, Eduardo A.F.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10
Y1 - 2019/10
N2 - The diagnosis of visceral leishmaniasis (VL) presents problems due to the toxicity and/or high cost of drugs. In addition, no vaccine exists to protect against human disease. In this study, the antigenicity and immunogenicity of amastin protein were evaluated in L. infantum–infected dogs and humans. For the diagnosis, besides the recombinant protein, 1 linear B-cell epitope was synthetized and evaluated in serological assays. Results showed high sensitivity and specificity values to detect the disease when both antigens were employed against a canine and human serological panel. By contrast, when using rA2 and a soluble Leishmania antigenic preparation, sensitivity and specificity values proved to be lower. A preliminary immunogenicity study showed that the amastin protein induced high IFN-γ and low IL-10 production in stimulated PBMC derived from treated VL patients and healthy subjects, thus suggesting a potential use of this protein as an immunogen to protect against human disease.
AB - The diagnosis of visceral leishmaniasis (VL) presents problems due to the toxicity and/or high cost of drugs. In addition, no vaccine exists to protect against human disease. In this study, the antigenicity and immunogenicity of amastin protein were evaluated in L. infantum–infected dogs and humans. For the diagnosis, besides the recombinant protein, 1 linear B-cell epitope was synthetized and evaluated in serological assays. Results showed high sensitivity and specificity values to detect the disease when both antigens were employed against a canine and human serological panel. By contrast, when using rA2 and a soluble Leishmania antigenic preparation, sensitivity and specificity values proved to be lower. A preliminary immunogenicity study showed that the amastin protein induced high IFN-γ and low IL-10 production in stimulated PBMC derived from treated VL patients and healthy subjects, thus suggesting a potential use of this protein as an immunogen to protect against human disease.
KW - Amastin
KW - Diagnosis
KW - Recombinant proteins
KW - Response immune
KW - Synthetic peptides
KW - Visceral leishmaniasis
UR - http://www.scopus.com/inward/record.url?scp=85066237484&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2019.04.015
DO - 10.1016/j.diagmicrobio.2019.04.015
M3 - Article
C2 - 31155395
AN - SCOPUS:85066237484
SN - 0732-8893
VL - 95
SP - 134
EP - 143
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 2
ER -